Erfo 9M 2026 Adjusted EBITDA Rises 11% YoY to €1.8 Million

PUBT · 3d ago
Erfo 9M 2026 Adjusted EBITDA Rises 11% YoY to €1.8 Million
  • Erfo’s adjusted EBITDA rose 11% year over year to €1.8 million in the first nine months of 2026, benefiting from improved parent-company profitability.
  • Revenue slipped to €7.4 million, while Fit and Go revenue dropped 27% year over year to €1.7 million.
  • Medical Division revenue jumped 80% year over year to €469,000; foreign revenue climbed 29% to €1 million.
  • Net cash more than doubled to €1.3 million at September 30, 2026, from December 31, 2025.
  • The European network expanded to 282 centers at September 30; Fit and Go added three locations in October.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorio Farmaceutico Erfo S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20259-36-2026_TELEBORSA.pdf), on November 19, 2026, and is solely responsible for the information contained therein.